JP MORGAN/CALL/EDWARDS LIFESCIENCES/130/0.1/15.11.24 | Real-time Bid/Ask 01:27:51 03/06/2024 pm IST | ||
| 0.018 EUR / 0.12 EUR | +213.64% |
|
| 1 month | -8.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about EDWARDS LIFESCIENCES CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 31/24/31 | 0.022 | +15.79% |
| 30/24/30 | 0.019 | +18.75% |
| 29/24/29 | 0.016 | -30.43% |
| 28/24/28 | 0.023 | +4.55% |
| 27/24/27 | 0.022 | +4.76% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 02:54 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | EDWARDS LIFESCIENCES CORPORATION |
| Issuer | J.P. Morgan |
| WKN | JK58HZ |
| ISIN | DE000JK58HZ5 |
| Date issued | 11/04/2024 |
| Strike | 130 $ |
| Maturity | 15/11/2024 (166 Days) |
| Parity | 10 : 1 |
| Emission price | 0.12 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.093 € |
|---|---|
| Lowest since issue | 0.015 € |
| Spread | 0.102 € |
| Spread % | 85.00% |
Company Profile
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Sector
-
Ratings for Edwards Lifesciences Corporation
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Edwards Lifesciences Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
86.89
USD
Average target price
96.55
USD
Spread / Average Target
+11.12%
- Stock Market
- Warrants
- Warrant
